Author

A. Noronha

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Bioengineering· 1 Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 2 Approach:statistical model· 2 Assay:bulk RNA-seq· 1 Research Focus:cell type annotation· 1 Approach:deep learning· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1 Research Focus:gene regulatory network inference· 1

Frequent Co-Authors

Y. Yarden· 2 shared A. H. C. van Kampen· 1 shared A. Tennenhouse· 1 shared D. Fass· 1 shared E. Makowski· 1 shared E. Sofyali· 1 shared H. Wilhelm· 1 shared I. Zaretsky· 1 shared

Activity by Year

2020-2022 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 25 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersBioengineering

Y. Yarden

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Reliable energy-based antibody humanization and stabilization

A. Tennenhouse, L. Khmelnitsky, R. Khalaila, N. Yeshaya, A. Noronha, M. Lindzen, E. Makowski, I. Zaretsky, Y. Fridmann Sirkis, Y. Galon-Wolfenson, P. M. Tessier, J. Abramson, Y. Yarden, D. Fass, S. J. Fleishman

The paper introduces CUMAb, a computational method for humanizing antibodies that improves stability and binding by systematically grafting CDRs onto human frameworks and ranking designs using Rosetta simulations.

bioRxiv · Aug 14, 2022Bioengineering

Time-resolved profiling reveals ATF3 as a novel mediator of endocrine resistance in breast cancer

S. Borgoni, E. Sofyali, M. Soleimani Dodaran, H. Wilhelm, K. Mueller-Decker, R. Will, A. Noronha, P. J. Verschure, Y. Yarden, L. Magnani, A. H. C. van Kampen, P. D. Moerland, S. Wiemann

This study identifies ATF3 as a novel mediator of endocrine resistance in breast cancer through time-resolved profiling and validates its role in key signaling pathways and clinical relevance.

bioRxiv · Jun 8, 2020Cancer Biology